Demographic and baseline disease characteristics of the all-treated population
| Characteristic . | N = 117 . |
|---|---|
| Sex, n (%) | |
| Male | 73 (62.4) |
| Female | 44 (37.6) |
| Age, median (range), y | 37.0 (19-87) |
| Age group, n (%) | |
| <60 years | 91 (77.8) |
| ≥60 years | 26 (22.2) |
| Region, n (%) | |
| North America | 56 (47.9) |
| Europe | 61 (52.1) |
| Race, n (%) | |
| White | 101 (86.3) |
| Black or African American | 5 (4.3) |
| Asian | 3 (2.6) |
| Native Hawaiian or Pacific Islander | 1 (0.9) |
| Other | 5 (4.3) |
| Missing | 2 (1.7) |
| Ethnicity, n (%) | |
| Hispanic or Latino | 7 (6.0) |
| Not Hispanic or Latino | 104 (88.9) |
| Missing | 6 (5.1) |
| ECOG performance status score, n (%) | |
| 0 | 64 (54.7) |
| 1 | 47 (40.2) |
| 2 | 6 (5.1) |
| Extranodal, n (%) | 47 (40.2) |
| Constitutional symptoms, n (%) | |
| Absence of B symptoms | 62 (53.0) |
| B symptoms | 50 (42.7) |
| Missing | 5 (4.3) |
| Disease stage as study entry, n (%) | |
| I/II | 28 (23.9) |
| III/IV | 89 (76.1) |
| Previous systemic therapies, median (range) | 6.0 (3-19) |
| Previous systemic therapies, n (%) | |
| ≤5 previous lines | 45 (38.5) |
| 6-7 previous lines | 30 (25.6) |
| ≥8 previous lines | 42 (35.9) |
| Previous radiotherapy, n (%) | 55 (47.0) |
| Previous HSCT, n (%) | 74 (63.2) |
| Only autologous | 59 (50.4) |
| Only allogeneic | 3 (2.6) |
| Both | 12 (10.3) |
| None | 43 (36.8) |
| Response to first line of systemic therapy,∗n (%) | |
| Relapse | 79 (67.5) |
| Refractory† | 29 (24.8) |
| Response to most recent line of systemic therapy,∗n (%) | |
| Relapse | 36 (30.8) |
| Refractory† | 66 (56.4) |
| Response to last checkpoint inhibitor,∗n (%) | |
| Relapse | 33 (28.2) |
| Refractory† | 71 (60.7) |
| Characteristic . | N = 117 . |
|---|---|
| Sex, n (%) | |
| Male | 73 (62.4) |
| Female | 44 (37.6) |
| Age, median (range), y | 37.0 (19-87) |
| Age group, n (%) | |
| <60 years | 91 (77.8) |
| ≥60 years | 26 (22.2) |
| Region, n (%) | |
| North America | 56 (47.9) |
| Europe | 61 (52.1) |
| Race, n (%) | |
| White | 101 (86.3) |
| Black or African American | 5 (4.3) |
| Asian | 3 (2.6) |
| Native Hawaiian or Pacific Islander | 1 (0.9) |
| Other | 5 (4.3) |
| Missing | 2 (1.7) |
| Ethnicity, n (%) | |
| Hispanic or Latino | 7 (6.0) |
| Not Hispanic or Latino | 104 (88.9) |
| Missing | 6 (5.1) |
| ECOG performance status score, n (%) | |
| 0 | 64 (54.7) |
| 1 | 47 (40.2) |
| 2 | 6 (5.1) |
| Extranodal, n (%) | 47 (40.2) |
| Constitutional symptoms, n (%) | |
| Absence of B symptoms | 62 (53.0) |
| B symptoms | 50 (42.7) |
| Missing | 5 (4.3) |
| Disease stage as study entry, n (%) | |
| I/II | 28 (23.9) |
| III/IV | 89 (76.1) |
| Previous systemic therapies, median (range) | 6.0 (3-19) |
| Previous systemic therapies, n (%) | |
| ≤5 previous lines | 45 (38.5) |
| 6-7 previous lines | 30 (25.6) |
| ≥8 previous lines | 42 (35.9) |
| Previous radiotherapy, n (%) | 55 (47.0) |
| Previous HSCT, n (%) | 74 (63.2) |
| Only autologous | 59 (50.4) |
| Only allogeneic | 3 (2.6) |
| Both | 12 (10.3) |
| None | 43 (36.8) |
| Response to first line of systemic therapy,∗n (%) | |
| Relapse | 79 (67.5) |
| Refractory† | 29 (24.8) |
| Response to most recent line of systemic therapy,∗n (%) | |
| Relapse | 36 (30.8) |
| Refractory† | 66 (56.4) |
| Response to last checkpoint inhibitor,∗n (%) | |
| Relapse | 33 (28.2) |
| Refractory† | 71 (60.7) |